Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 26-50 of 127 citing articles:

Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data
Neil H. Shear, Keith A. Betts, Ahmed M. Soliman, et al.
Journal of the American Academy of Dermatology (2021) Vol. 85, Iss. 3, pp. 572-581
Open Access | Times Cited: 50
Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial
James Cheng‐Chung Wei, Tae‐Hwan Kim, Mitsumasa Kishimoto, et al.
Annals of the Rheumatic Diseases (2021) Vol. 80, Iss. 8, pp. 1014-1021
Open Access | Times Cited: 43
Adverse events associated with anti-IL-17 agents for psoriasis and psoriatic arthritis: a systematic scoping review
Jiao Wang, Chunxiao Wang, Liu Liu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 21
Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-Analysis
April W. Armstrong, Richard B. Warren, Yichen Zhong, et al.
Dermatology and Therapy (2023) Vol. 13, Iss. 11, pp. 2839-2857
Open Access | Times Cited: 19
Efficacy and Safety of Brodalumab, an Anti-interleukin-17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16-Week Results of a Randomized Clinical Trial
Yukari Okubo, Satomi Kobayashi, Masamoto Murakami, et al.
American Journal of Clinical Dermatology (2024)
Open Access | Times Cited: 7
Celastrol regulates psoriatic inflammation and autophagy by targeting IL-17A
Aeri Park, Tae-Hwe Heo
Biomedicine & Pharmacotherapy (2024) Vol. 172, pp. 116256-116256
Open Access | Times Cited: 6
Systematic review with meta‐analysis: risk of new onset IBD with the use of anti‐interleukin‐17 agents
Akihiro Yamada, Jingzhou Wang, Yuga Komaki, et al.
Alimentary Pharmacology & Therapeutics (2019) Vol. 50, Iss. 4, pp. 373-385
Closed Access | Times Cited: 53
Redefining the therapeutic objective in psoriatic patients candidates for biological therapy
G. Carretero, L. Puig, J.M. Carrascosa, et al.
Journal of Dermatological Treatment (2017) Vol. 29, Iss. 4, pp. 334-346
Open Access | Times Cited: 51
Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials
Lian Cui, Rongfen Chen, Smriti Subedi, et al.
International Immunopharmacology (2018) Vol. 62, pp. 46-58
Closed Access | Times Cited: 50
Biologic therapies targeting the interleukin (IL)‐23/IL‐17 immune axis for the treatment of moderate‐to‐severe plaque psoriasis: a systematic review and meta‐analysis
C Erichsen, P. E. H. Jensen, Klaus F. Kofoed
Journal of the European Academy of Dermatology and Venereology (2019) Vol. 34, Iss. 1, pp. 30-38
Closed Access | Times Cited: 44
Long‐term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE‐1)*
Kim Papp, Alan Menter, C. Leonardi, et al.
British Journal of Dermatology (2020) Vol. 183, Iss. 6, pp. 1037-1048
Open Access | Times Cited: 44
Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis
Matthias Augustin, Jo Lambert, Carla L. Zema, et al.
JAMA Dermatology (2020) Vol. 156, Iss. 12, pp. 1344-1344
Open Access | Times Cited: 41
Scalp Psoriasis: A Literature Review of Effective Therapies and Updated Recommendations for Practical Management
Megan Mosca, Julie Hong, Edward Hadeler, et al.
Dermatology and Therapy (2021) Vol. 11, Iss. 3, pp. 769-797
Open Access | Times Cited: 34
English version of Japanese guidance for use of biologics for psoriasis (the 2022 version)
Hidehisa Saeki, Tomotaka Mabuchi, Akihiko Asahina, et al.
The Journal of Dermatology (2022) Vol. 50, Iss. 2
Open Access | Times Cited: 24
The origin and role of innate lymphoid cells in the lung
Dengming Lai, Qiang Shu, Jie Fan
Military Medical Research (2016) Vol. 3, Iss. 1
Open Access | Times Cited: 44
Psoriatic disease treatment nowadays: unmet needs among the “jungle of biologic drugs and small molecules”
Matteo Megna, Anna Balato, Maddalena Napolitano, et al.
Clinical Rheumatology (2018) Vol. 37, Iss. 7, pp. 1739-1741
Open Access | Times Cited: 44
Safety and Efficacy of Brodalumab for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis
Attia Attia, Abdelrahman Ibrahim Abushouk, Hussien Ahmed, et al.
Clinical Drug Investigation (2017) Vol. 37, Iss. 5, pp. 439-451
Closed Access | Times Cited: 41
The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis
L. Sawyer, Iain Fotheringham, Emily K. Wright, et al.
Journal of Dermatological Treatment (2018) Vol. 29, Iss. 6, pp. 557-568
Open Access | Times Cited: 40
Long‐term clinical safety and efficacy of brodalumab in the treatment of Japanese patients with moderate‐to‐severe plaque psoriasis
Yoshinori Umezawa, Hidemi Nakagawa, Hiroaki Niiro, et al.
Journal of the European Academy of Dermatology and Venereology (2016) Vol. 30, Iss. 11, pp. 1957-1960
Closed Access | Times Cited: 39
IL-17A-targeting fenofibrate attenuates inflammation in psoriasis by inducing autophagy
Aeri Park, Tae‐Hwe Heo
Life Sciences (2023) Vol. 326, pp. 121755-121755
Closed Access | Times Cited: 12
Short-term risk and long-term incidence rate of infection and malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis
S. Wu, Yuanyuan Xu, Lihua Yang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 12
Risk of candidiasis associated with interleukin-17 inhibitors: Implications and management
Hazrat Bilal, Muhammad Nadeem Khan, Sabir Khan, et al.
Mycology: An International Journal on Fungal Biology (2023) Vol. 15, Iss. 1, pp. 30-44
Open Access | Times Cited: 11
Effectiveness of Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: A Retrospective, Real-World Multicenter Study with a Focus on Obese and Multi-Failure Patients—IL PSO (Italian Landscape Psoriasis)
Diego Orsini, Dario Graceffa, Martina Burlando, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 4, pp. 1087-1087
Open Access
Intra-Class Interleukin-(IL)-17 Blocker Switching: Ixekizumab as a Solution for Secukinumab Non-responders in Secondary Biologic Failure in Psoriasis
Abhishek De, Disha Chakraborty, Sk Shahriar Ahmed
Cureus (2025)
Open Access
IL‐17 and IL‐23 inhibitors dose spacing in adult psoriatic patients: a real‐world pilot study
Luca Mastorino, Paolo Dapavo, Michela Ortoncelli, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2025)
Open Access

Scroll to top